SCHEMBL696773

SCHEMBL696773

COc1ccc(CN[C@H](C)CO)cc1

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.56
CASR P41180 1/20 0.53
ALDH1A1 P00352 3/20 0.51
PKM P14618 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
HTT P42858 1/20 0.50
LMNA P02545 1/20 0.50
TDP1 Q9NUW8 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
ADRB2 P07550 1/20 0.46
CHRM2 P08172 1/20 0.46
SLC6A4 P31645 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3508651 1.00 MEN1 (0.58) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL1458778 1.00 MEN1 (0.58) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL19865693 0.84 L3MBTL1 (0.57) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL25269832 0.83 TRPV3 (0.51) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL25269831 0.83 TRPV3 (0.51) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL13995687 0.82 ALDH1A1 (0.58) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL20502219 0.82 L3MBTL1 (0.56) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL10263818 0.82 L3MBTL1 (0.56) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL8610978 0.81 ALDH1A1 (0.57) MEN1KMT2AL3MBTL1CASRALDH1A1
SCHEMBL278630 0.81 CASR (0.58) MEN1KMT2AL3MBTL1CASRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 EP disclosed
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives RICHTER GEDEON NYRT. (HU) 2025-11-18 US disclosed
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2023-09-14 US disclosed
EP-4192833-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES Richter Gedeon Nyrt. (HU) 2023-06-14 EP disclosed
CN-116075514-A Pharmacologically active heterocyclic substituted pyrazolo [1,5-a ] pyrimidine derivatives 吉瑞工厂 2023-05-05 CN disclosed
CN-109952305-B Piperazino heteroaryl derivative, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2022-06-21 CN disclosed
US-11247998-B2 Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2022-02-15 US disclosed
EP-3660018-A1 PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE Jiangsu Hengrui Medicine Co., Ltd. (CN) 2020-06-03 EP disclosed
US-20200157111-A1 PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE JIANGSU HENGRUI MEDICINE CO., LTD. (CN) 2020-05-21 US disclosed
US-8569294-B2 2-(cyclic amino)-pyrimidone derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-10-29 US disclosed
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-09-17 US disclosed
EP-2001863-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2008-12-17 EP disclosed
WO-2007119463-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES AS TPK1 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-10-25 WO disclosed
US-6958402-B2 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER, INC. (US) 2005-10-25 US disclosed
US-20040254164-A1 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER INC. (US) 2004-12-16 US disclosed
US-6713496-B2 3-(imidazolyl)-2-alkoxypropanoic acids PFIZER INC 2004-03-30 US disclosed
US-20030199522-A1 3-(Imidazolyl)-2-alkoxypropanoic acids PFIZER INC. 2003-10-23 US disclosed
WO-2003061652-A1 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIA INHIBITORS PFIZER LIMITED (GB) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199522-A1 3-(Imidazolyl)-2-alkoxypropanoic acids F2, FGB, F7 MEN1 1716/4885KMT2A 3944/4885L3MBTL1 1168/4885
US-11247998-B2 Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine IKZF2, WEE1, NOTUM MEN1 2907/4885KMT2A 2224/4885L3MBTL1 4582/4885
US-20090233918-A1 2-(CYCLIC AMINO)-PYRIMIDONE DERIVATIVES MAPT, PRMT1, PSEN1 MEN1 3362/4885KMT2A 701/4885L3MBTL1 686/4885
US-20040254164-A1 3-(imidazolyl)-2-alkoxypropanoic acids F2, FGB, F7 MEN1 1756/4885KMT2A 4061/4885L3MBTL1 1241/4885
US-20200157111-A1 PIPERAZINE HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR AND USE OF SAME IN MEDICINE IKZF2, WEE1, NOTUM MEN1 2907/4885KMT2A 2224/4885L3MBTL1 4582/4885
US-20230286988-A1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES GABRA5, GABRA1, P2RX5 MEN1 3529/4885KMT2A 4117/4885L3MBTL1 4823/4885
US-12473293-B2 Pharmacologically active heterocyclic-substituted pyrazolo[1,5-a]pyrimidine derivatives GABRA5, GABRA1, P2RX5 MEN1 3529/4885KMT2A 4117/4885L3MBTL1 4823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.